BIONICS

Trial design: Patients undergoing PCI were randomized to a ridaforolimus-eluting stent (n = 958) vs. a zotarolimus-eluting stent (n = 961).



Results

- Target lesion failure at 12 months: 5.4% of the ridaforolimus-eluting stent group vs. 5.4% of the zotarolimus-eluting stent group (p for noninferiority = 0.001)
- Definite/probable stent thrombosis: 0.4% vs. 0.6% (p = 0.53); respectively, for ridaforolimus vs. zotarolimus

Conclusions

- Among patients undergoing PCI, the novel ridaforolimus-eluting stent was noninferior to the zotarolimus-eluting stent
- The ridaforolimus-eluting stent was associated with a similar incidence of target lesion failure compared with the zotarolimus-eluting stent

Kandzari DE, et al. Circulation 2017;Aug 9:[Epub]